🇺🇸 FDA
Pipeline program

Febuxostat

TMX-67_204

Phase 2 small_molecule completed

Quick answer

Febuxostat for Joint Damage is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Joint Damage
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials